Intellia Therapeutics (NTLA) Share-based Compensation (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Share-based Compensation data on file, last reported at $13.5 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $13.5 million, down 38.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.9 million (down 49.37% YoY), and the FY2025 annual result was $80.2 million, down 48.0% from the prior year.
• Share-based Compensation declined to $13.5 million in Q1 2026 per NTLA's latest filing, from $16.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $40.9 million in Q2 2024 and troughed at $13.5 million in Q1 2026.
• A 5-year average of $27.8 million and a median of $25.2 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 187.84% in 2022, then sank 57.75% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $24.6 million in 2022, then surged by 42.3% to $35.0 million in 2023, then climbed by 13.05% to $39.6 million in 2024, then slumped by 57.75% to $16.7 million in 2025, then fell by 19.48% to $13.5 million in 2026.
• Business Quant data shows NTLA's Share-based Compensation at $13.5 million in Q1 2026, $16.7 million in Q4 2025, and $19.6 million in Q3 2025.